Founded in 2023
About
Esphera SynBio has a platform technology allowing for the generation of designer exosomes, either in vivo or ex vivo. These engineered exosomes can be targeted to specific cells in the body to deliver a defined payload or payloads. This is achieved through the expression of transgenes in a producer cell leading to the production of multimeric proteins that accumulate in budding exosomes. There is great flexibility in the nature of the cells that can be targeted (tumour cells, immune cells, etc.) and the therapeutic payloads loaded, including enzymes (toxic, immune-stimulatory, replacement), as well as RNAs (miRNA, siRNA, mRNA or self-replicating RNAs). Esphera focuses on applying this technology to the treatment of infectious diseases and cancer.
McMaster Founder
Brian Lichty (Faculty Health Sciences).